About
Pi-Cardia is a global medical device company based in Israel, focused on developing innovative, non-implant, catheter-based solutions for structural heart valve disease. The company specializes in next-generation valve repair technologies that offer safe and effective treatment options without the need for permanent implants. Their core products include the ShortCut™ Device, the first dedicated leaflet splitting device designed to enhance the safety of Transcatheter Aortic Valve Replacement (TAVR) procedures, and the Leaflex™ Device, which mechanically scores calcified valve leaflets to improve flexibility and valve function. Both devices are investigational in the U.S. and have received FDA market clearance and Breakthrough Device Designation. Pi-Cardia's technologies aim to address critical needs in heart valve disease treatment, particularly for patients with calcified aortic stenosis and those at risk during valve replacement procedures. The company targets cardiologists, cardiac surgeons, and healthcare providers, striving to improve patient outcomes through minimally invasive interventions.
Technologies
Keywords
Company Information
-
Employees 67
-
Founded 2009
-
Annual Revenue $2900000
-
Total Funding $37000000
Location
5 David Fikes Street, Rehovot, Center District, Israel, 7632805